{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:19:23Z","timestamp":1795126763652,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the real-world effect of the IL-12\/23 inhibitor ustekinumab or of a tumour necrosis factor inhibitor (TNFi) on patient-reported outcomes (PRO) and their association with effectiveness endpoints in psoriatic arthritis (PsA) patients over 3 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In PsABio (NCT02627768), a prospective, observational study, patients with PsA that were prescribed first- to third-line ustekinumab or a TNFi, and remained on that drug for 3 years, were analysed for change in baseline in PROs (EuroQol-5 dimensions health state VAS [EQ-5D VAS], 12-item Psoriatic Arthritis Impact of Disease questionnaire [PsAID-12; range 0\u201310], Work Productivity and Activity Impairment for Psoriatic Arthritis questionnaire [WPAI; results expressed as a percentage for each domain]), and the association between PROs and WPAI with effectiveness endpoints, clinical disease activity index for psoriatic arthritis (cDAPSA), low disease activity (LDA)\/remission, minimal disease activity (MDA) and very low disease activity (VLDA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 437 patients (mean age 49.1 years, 47.8% female), at 3 years, ustekinumab and TNFi treatment led to comparable improvements in EQ-5D VAS; mean change from baseline (95% confidence intervals [CI]) was 11.0 (6.5; 15.4) and 18.9 (14.0; 23.9), respectively. Both groups improved PsAID-12 after 3 years; mean change from baseline (95% CI) was \u22122.9 (\u22123.2; \u22122.5) and \u22123.5 (\u22123.9; \u22123.2), respectively. At baseline, due to their PsA, TNFi-treated patients had lower work productivity compared to ustekinumab-treated patients; mean productivity reduction (95% CI) was 58.8 [52.4; 65.2] and 43.3 [35.6; 51.1]. Over 3 years, TNFi-treated patients had a greater improvement in work productivity compared to ustekinumab-treated patients, ultimately leaving work productivity to be comparable between groups; mean improvement (95% CI) was 44.5% (38.4; 50.6) and 24.9% (15.8; 34.0), respectively. A similar trend was observed in activity impairment. Patients in both treatment groups who achieved effectiveness endpoints, cDAPSA LDA\/remission, MDA, and VLDA had greater improvement in PROs and WPAI than patients who did not achieve these endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>At 3 years, improvements in PROs following ustekinumab or TNFi treatment were generally comparable; however, TNFi-treated patients achieved a greater improvement in work productivity, although this group started from a lower baseline. Achievement of effectiveness endpoints, independent of treatment group, also improved PROs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, NCT02627768. Registered on 11 December 2015<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03058-y","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T08:54:43Z","timestamp":1687510483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study"],"prefix":"10.1186","volume":"25","author":[{"given":"Laure","family":"Gossec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatr\u00edz","family":"Joven-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Korotaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"issue":"1","key":"3058_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, Leung YY, deWit M, Scher JU, Mease PJ. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"3058_CR2","doi-asserted-by":"publisher","first-page":"rkaa033","DOI":"10.1093\/rap\/rkaa033","volume":"4","author":"J Rech","year":"2020","unstructured":"Rech J, Sticherling M, Stoessel D, Biermann MHC, Haberle BM, Reinhardt M. Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract. 2020;4(2):rkaa033.","journal-title":"Rheumatol Adv Pract"},{"key":"3058_CR3","doi-asserted-by":"crossref","unstructured":"Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6(1):e001223.","DOI":"10.1136\/rmdopen-2020-001223"},{"issue":"1","key":"3058_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/acr.24412","volume":"73","author":"G Haugeberg","year":"2021","unstructured":"Haugeberg G, Lund Nilsen TI, Kavanaugh A, Thomsen RS, Gulati AM, Hoff M. Physical and psychosocial burden of psoriatic arthritis: longitudinal data from a population-based study in Norway. Arthritis Care Res (Hoboken). 2021;73(1):138\u201345.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"3058_CR5","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/jcm9103103","volume":"9","author":"B Batko","year":"2020","unstructured":"Batko B. Patient-centered care in psoriatic arthritis-a perspective on inflammation, disease activity, and psychosocial factors. J Clin Med. 2020;9(10):3103.","journal-title":"J Clin Med"},{"issue":"3","key":"3058_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(3):351\u201360.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"3058_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001240","volume":"6","author":"PG Conaghan","year":"2020","unstructured":"Conaghan PG, Alten R, Deodhar A, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Strand V. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open. 2020;6(2): e001240.","journal-title":"RMD Open"},{"issue":"5","key":"3058_CR8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/bjd.13691","volume":"172","author":"H Kitchen","year":"2015","unstructured":"Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol. 2015;172(5):1210\u201321.","journal-title":"Br J Dermatol"},{"key":"3058_CR9","first-page":"243","volume":"7","author":"P Davari","year":"2014","unstructured":"Davari P, Leo MS, Kamangar F, Fazel N. Ustekinumab for the treatment of psoriatic arthritis: an update. Clin Cosmet Investig Dermatol. 2014;7:243\u20139.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9894","key":"3058_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139.","journal-title":"Lancet"},{"issue":"6","key":"3058_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen Y-K, Doyle MK, Mendelsohn AM, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, m. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3058_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, Fakharzadeh S, Goyal K, Calabro S, Langholff W, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3058_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000779","volume":"5","author":"A-S Vandendorpe","year":"2019","unstructured":"Vandendorpe A-S, de Vlam K, Lories R. Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments. RMD Open. 2019;5(1): e000779.","journal-title":"RMD Open"},{"issue":"4","key":"3058_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-017-0642-z","volume":"19","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, Coates L. The changing face of clinical trials in psoriatic arthritis. Curr Rheumatol Rep. 2017;19(4):21.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"3058_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"11","key":"3058_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","volume":"80","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Siebert S, Korotaeva TV, Selmi C, Bergmans P, Gremese E, Joven-Ibanez B, Katsifis G, Noel W, Nurmohamed MT, et al. Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis. 2021;80(11):1419\u201328.","journal-title":"Ann Rheum Dis"},{"key":"3058_CR17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2023-eular.3506","volume":"82","author":"L Gossec","year":"2023","unstructured":"Gossec L, Siebert S, Bergmans P, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis. 2023;82:496\u2013506.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3058_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","volume":"81","author":"L Gossec","year":"2022","unstructured":"Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibanez B, Korotaeva TV, Lavie F, Noel W, Nurmohamed MT, et al. Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022;81(6):823\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3058_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","volume":"51","author":"W Tillett","year":"2012","unstructured":"Tillett W. de-Vries C, McHugh NJ: Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012;51(2):275\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3058_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"3058_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1477-7525-6-94","volume":"6","author":"DK Whynes","year":"2008","unstructured":"Whynes DK. TOMBOLA Group: Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes. 2008;6:94.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"3058_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooaar I, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3058_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3058_CR24","doi-asserted-by":"publisher","unstructured":"Tang K, Beaton DE, Boonen A, Gignac MA, Bombardier C. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S337\u201349. https:\/\/doi.org\/10.1002\/acr.20633.","DOI":"10.1002\/acr.20633"},{"issue":"5","key":"3058_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3058_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","volume":"76","author":"D Aletaha","year":"2017","unstructured":"Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis. 2017;76(2):418\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3058_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3899\/jrheum.150826","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43(2):371\u20135.","journal-title":"J Rheumatol"},{"issue":"3","key":"3058_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJMe1906559","volume":"381","author":"D Harrington","year":"2019","unstructured":"Harrington D, D\u2019Agostino RB Sr, Gatsonis C, Hogan JW, Hunter DJ, Normand ST, Drazen JM, Hamel MB. New Guidelines for Statistical Reporting in the Journal. N Engl J Med. 2019;381(3):285\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"3058_CR29","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/acr.23000","volume":"68","author":"P Rahman","year":"2016","unstructured":"Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, Li S, Wang Y, Song M, Mendelsohn A, et al. Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1812\u201322.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3058_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-021-05893-3","volume":"41","author":"O Karadag","year":"2022","unstructured":"Karadag O, Dalkilic E, Ayan G, Kucuksahin O, Kasifoglu T, Yilmaz N, Koca SS, Yazisiz V, Erten PT, Sayarlioglu M, et al. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clin Rheumatol. 2022;41(1):85\u201394.","journal-title":"Clin Rheumatol"},{"key":"3058_CR31","unstructured":"Turkiewicz A, Gellett AM, Kerr L, Birt J, Gratacos J. Long-term effect of ixekizumab on patient-reported outcomes in patients with Psa and inadequate response to TNF inhibitors: 2-year follow-up from a phase 3 study [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). https:\/\/acrabstracts.org\/abstract\/long-term-effect-of-ixekizumab-on-patient-reported-outcomes-in-patients-with-psa-and-inadequate-response-to-tnf-inhibitors-2-year-follow-up-from-a-phase-3-study\/. Accessed 9 Mar 2022."},{"issue":"10","key":"3058_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/rheumatology\/key161","volume":"57","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaci D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford). 2018;57(10):1777\u201388.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3058_CR33","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(21)00354-4","volume":"4","author":"V Strand","year":"2022","unstructured":"Strand V, Kaeley GS, Bergman MJ, Gladman D, Coates L, Sherif B, Hur P, Parikh B, Gilloteau I, Mease P. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Lancet Rheumatol. 2022;4(3):e208\u201319.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"3058_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002457","volume":"8","author":"LC Coates","year":"2022","unstructured":"Coates LC, Smolen JS, Mease PJ, Husni ME, Merola JF, Lespessailles E, Kishimoto M, Macpherson L, Bradley AJ, Bolce R, et al. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis. RMD Open. 2022;8(2): e002457.","journal-title":"RMD Open"},{"issue":"10012","key":"3058_CR35","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489\u201398.","journal-title":"Lancet"},{"issue":"1","key":"3058_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s41669-020-00221-y","volume":"5","author":"MH Roberts","year":"2021","unstructured":"Roberts MH, Ferguson GT. Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. Pharmacoecon Open. 2021;5(1):3\u201311.","journal-title":"Pharmacoecon Open"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03058-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T08:57:52Z","timestamp":1687510672000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03058-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3058"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03058-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with ethics requirements as specified by the Independent Ethics Committee\/Institutional Review Board and by local regulations. Each participant signed a participation agreement\/informed consent form in line with local regulations and trial sponsor policy before data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LG reports personal fees from Janssen during the conduct of the study, research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis and UCB outside the submitted work. SS reports non-financial support from Janssen during the conduct of the study; personal fees from AbbVie, Biogen, Novartis and UCB; grants from Amgen (previously Celgene), Boehringer-Ingelheim and Bristol-Myers-Squibb; grants and personal fees from GlaxoSmithKline, Janssen and Eli Lilly outside the submitted work. PB reports personal fees from Janssen and personal fees from Johnson & Johnson during the conduct of the study. KdV reports personal and consulting fees from Janssen. EG reports payment or honoraria from AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Galapagos, GSK, Janssen, Novartis, Pfizer and Sanofi. BJI reports consulting fees from Amgen, Janssen and UCB; and payment or honoraria from AbbVie, Eli Lilly, Janssen, Novartis and UCB. TVK reports consulting\/speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Sandoz, BiOCAD, Pfizer and MCD. FL reports non-financial support from Janssen during the conduct of the study. WN is a full-time employee of and owns stock at Johnson & Johnson. MTN reports grants and non-financial support from Janssen during the conduct of the study; grants and personal fees from AbbVie and Eli Lilly; grants from Amgen, BMS and Pfizer; and grants from Galapagos outside the submitted work. PPS reports non-financial support from Janssen during the conduct of the study; grants and personal fees from AbbVie, Eli Lilly, Novartis and Pfizer; grants from UCB; and personal fees from MSD outside the submitted work. MS is a full-time Johnson & Johnson employee and reports non-financial support from Janssen during the conduct of the study. ET was an employee of Janssen during the conduct of the study and preparation of this paper. JSS received grants to his institution from Abbvie, Astro, AstraZeneca, Janssen, Lilly, Merck Sharpe & Dohme, Pfizer, and Roche and provided expert advice for, or had symposia speaking engagements with, AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, R-Pharma, Roche, Samsung, Sanofi, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}